Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study

This report has been verified by one or more authors of the original publication.

この研究はハイインパクトの可能性があります。 OEのAI駆動型ハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文が持つ可能性の高い影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することが可能になり、読者は将来の診療を形成する可能性が最も高い論文に集中することができます。

Eighty postmenopausal women with osteoporosis were randomized to one of three treatment groups: one received 2.5 units of growth hormone per day for 3 years; one received 1 unit of growth hormone per day for 3 years; one received placebo every day for 18 months. The double-blind phase of the trial lasted up to 18 months. The purpose of the study was to evaluate the effects of growth hormone therapy on bone quality and fracture risk 10 years after the start of treatment (7 years after treatment completion). Results demonstrated increases in bone mineral density and bone mineral content in both the 2.5 and 1.0U/d growth hormone groups relative to baseline, as well as placebo, up to the 4-year assessment period (ie. 1 year after treatment cessation). Thereafter, the effect of growth hormone therapy decreased in both treatment groups and continued to decline to approximately pre-treatment levels at the 10-year follow-up. There did not appear to be a marked difference in fracture rate between the 2.5 and 1.0U/d GH groups (10 and 15 fractures; respectively) and the placebo group (9 fractures) over the duration of the 10-year study duration.